Rasha Mahmoud Allam

Dr. Rasha Mahmoud Allam

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MEMahitab Ibrahim Eltohamy
Mahitab Ibrahim Eltohamy
OBOmnia Mohammed Badawy
Omnia Mohammed Badawy
NKNaglaa El Kinaai
Naglaa El Kinaai
ILIman Loay
Iman Loay
HNHanan Ramadan Nassar
Hanan Ramadan Nassar
MSMona Ali Sakr
Mona Ali Sakr
Objective: Triple negative breast cancer is an aggressive variant of breast cancer; it forms about 15% of breastcancer cases. It lacks the responsiveness to hormonal and targeted therapies. Anthracyclines remain the treatment optionfor these patients. Anthracyclines are cardiotoxic, so predicting sensitivity of response by biological predictors mayhave a role in selecting suitable candidates for these drugs. Material and methods: This study included 50 TNBCcases, from National Cancer Institute, Cairo University(NCI-CU), Egypt, who underwent surgery and received adjuvantchemotherapy. Archived blocks were obtained and immunostaining for Ki-67 LI and Fluorescent In situ Hybridization(FISH) technique to assess TOP2A gene copy number and chromosome 17CEP status were done. Analysis of associationbetween TOP2A alterations and CEP17 polysomy as well as Ki-67 LI with other clinicopathological parameters wasdone. Associations between the biological markers and event free survival (EFS) and overall survival (OS), were alsoperformed. Results: TOP2A alteration was seen in 9/50 cases (5 amplified and 4 deleted). CEP17 Polysomy was detectedin 14% of cases. Most of patients (80%) showed Ki-67 LI ≥20%. There was a significant association between TOP2Agene and CEP17 status. Outcome was better with abnormal TOP2A gene status and CEP17 polysomy, radiotherapyand combined anthracyclines and taxanes in the adjuvant setting, however P-values were not significant. Conclusion:TOP2A gene alterations and CEP17 polysomy may have prognostic and predictive role in TNBC treated with adjuvantAnthracyclines.

1 January 2017
Verified
Journal Article
Open access
PDF file
RARasha Mahmoud Allam
Rasha Mahmoud Allam
MNMaissa K Noaman
Maissa K Noaman
MMManar M Moneer
Manar M Moneer
IEInas A Elattar
Inas A Elattar
Purpose: To identify statistical errors and pitfalls in dissertations performed as part of the requirements for the Medical Doctorate (MD) degree at the National Cancer Institute (NCI), Cairo University (CU) to improve the quality of medical research. Methods: A critical assessment of 62 MD dissertations conducted in 3 departments at NCI, CU, between 2009 and 2013 was carried out regarding statistical methodology and presentation of the results. To detect differences in study characteristics over time, grouping was into two periods; 2009-2010 and 2011-2013. Results: Statistical methods were appropriate in only 13 studies (24.5%). The most common statistical tests applied were chi-square, log-rank, and Mann-Whitney tests. Four studies estimated sample size and/or power. Only 37.1% and 38.7% of dissertation results supported aims and answered the research questions, respectively. Most of results were misinterpreted (82.3%) with misuse of statistical terminology (77.4%). Tabular and graphical data display was independently informative in only 36 dissertations (58.1%) with accurate titles and labels in only 17 (27.4%). Statistical tests fulfilled the assumptions only in 29 studies; with evident misuse in 33. Ten dissertations reported non-significance regarding their primary outcome measure; the median power of the test was 35.5% (range: 6-60%). There was no significant change in the characteristics between the time periods. Conclusion: MD dissertations at NCI have many epidemiological and statistical defects that may compromise the external validity of the results. It is recommended to involve a biostatistician from the very start to improve study design, sample size calculation, end points estimation and measures.

29 December 2020 in JGH Open
Verified
Journal Article
Open access
PDF file
MSMohamed Shalaby
Mohamed Shalaby
TBTarek S El Baradie
Tarek S El Baradie
MSMohamed Salama
Mohamed Salama
HSHebat A M Shaaban
Hebat A M Shaaban
RARasha Mahmoud Allam
Rasha Mahmoud Allam
AAAmr Attia
Amr Attia
Background and Aim: Colorectal cancer (CRC) accounts for over 8% of all deaths each year, with 1.2 million new cases diagnosed annually worldwide. It represents the seventh most common cancer in Egypt. Early detection of peritoneal metastasis is a major challenge in such cases. It helps with the decision of the immediate application of intraperitoneal chemotherapy after resection. Meta‐analysis studies reported contrast evidence for a possible prognostic role of intraperitoneal free cancer cells (IPCCs) in peritoneal recurrence and survival after curative resection. In this work, we aim to evaluate the prevalence and impact of detecting free malignant cells in peritoneal fluid on survival and local recurrence and to estimate the incidence of peritoneal carcinomatosis (PC) during follow up.Methods: Design: This was a prospective cohort study. Settings: From June 2016 to December 2018, samples were collected from 104 patients who underwent abdominal surgery for colorectal cancer in the Egyptian National Cancer Institute. A total of 96 Egyptian CRC patients who underwent curative resection were enrolled. Intraoperative peritoneal lavage was performed to detect IPCC by conventional cytology. Patients with no residual tumor after surgery and no evidence of PC were followed up for a median 14 months. The cumulative 12‐month overall survival rate for patients with IPCC was 100% versus 86% for patients with negative cytology.Results: Our results demonstrated that the prevalence of IPCC in the peritoneal lavage was 11.5%. Peritoneal and local recurrence occurred at a higher rate in patients with cytology positive lavage (9.1% vs 6.3% and 9.1% vs 3.8%, respectively), although this was statistically insignificant. Distant metastasis occurred significantly in patients with positive cytology (45.5% vs 8.9%) with P‐value <0.001.The conventional cytology technique has a high specificity but less sensitivity.Conclusions: The presence of IPCC using conventional cytology was not an independent prognostic factor for the development of PC or survival.


30 May 2025 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RARasha M. Abdel-Hamid
Rasha M. Abdel-Hamid
RARasha Mahmoud Allam
Rasha Mahmoud Allam
LRLobna Refaat
Lobna Refaat
HNHend A. Nooh
Hend A. Nooh
FMFarida M. Mahmoud
Farida M. Mahmoud
SHSafaa S. Hassan
Safaa S. Hassan

1 November 2023 in The Egyptian Journal of Community Medicine
Verified
Journal Article
Closed access
RARasha Mahmoud Allam
Rasha Mahmoud Allam
OMOmnia Mohamed
Omnia Mohamed
YEYoustina Elamir
Youstina Elamir
MRMohamed Rahouma
Mohamed Rahouma
HSHala Aziz Shokralla
Hala Aziz Shokralla
Cancer patients, such as those with gynecological and breast malignancies, are at a higher risk of COVID-19 infection and severe illness. However, there is limited research on the acceptance and safety of COVID-19 vaccines, specifically in this population.Methods: We conducted a cross-sectional study involving 370 female breast and gynecological cancer patients. Data were collected on comorbidities, cancer diagnosis and stage, treatment modalities, COVID-19 infection history, severity, timing of infection in relation to chemotherapy, COVID-19 vaccination status, and vaccine side effects.Results: Among the study population, 40.3% have been received the COVID-19 vaccine, 52.2% postponed it, and 7.6% were refusing vaccination. Sinovac vaccine was the most commonly received in the chemotherapy group (56%), followed by Pfizer and AstraZeneca (18.7% each), and Sputnik and Johnson (1.3% and 5.3%, respectively). Patients with a higher level of education were more likely to refuse vaccination. Refusal rate to COVID-19 vaccine was higher in gynecological malignancy cases than female breast cancer cases (72.97% vs. 56.42%, p-value = 0.009). Vaccine side effects were reported in varying percentages, with AstraZeneca and Pfizer having the highest rates (41.7% and 33.3%, respectively), while 95.6% of Sinovac receiver reported no side effects (p < 0.001). Cases with Gynecological malignancies had an increased risk of developing side effects post-COVID-19 vaccination (29.2%, p-value = 0.018, Odds Ratio 3.54, 95% CI 1.240-10.147).Conclusion: Our findings highlight a higher vaccination refusal rate between elderly patients with advanced stage gynecological cancers. However no major safety concerns associated with receiving COVID-19 vaccination during chemotherapy treatment.